Today: 10 June 2026
Macquarie share price rises as ASX hits fresh highs; new filings flag big stakes
26 February 2026
1 min read

Macquarie share price rises as ASX hits fresh highs; new filings flag big stakes

Sydney, Feb 26, 2026, 18:06 AEDT — Market closed

  • Macquarie Group finished the day 1.2% higher at A$209.55.
  • Macquarie has filed after surpassing the 5% “substantial holder” threshold in both Tabcorp and Downer EDI, according to disclosures.
  • Mark the calendar: Macquarie’s full-year results are due May 8.

Macquarie Group Ltd (MQG.AX) ended Thursday’s session at A$209.55, up 1.2%. Shares moved between A$208.88 and A$211.10 during the day. That’s a gain of A$2.43 from Wednesday’s A$207.12 close.

Australian stocks kept climbing through record highs on Thursday afternoon, the S&P/ASX 200 breaking fresh ground for a second day, powered by gains in banks and heavyweight miners. Looking to Friday, traders will watch for earnings from Coles, Harvey Norman, TPG Telecom, PEXA and Virgin Australia—results that could quickly swing the mood.

Why does that matter for Macquarie? Its earnings hinge on the markets—commodities trades, asset management fees, the works—and the share price tends to move with swings in risk sentiment. Investors also keep one eye on the paperwork: Macquarie continues to post a regular stream of substantial-holding notices.

This week, a filing revealed Macquarie Group and its affiliates have pushed past the 5% disclosure mark in Tabcorp Holdings, officially becoming a “substantial holder” under Australian regulation. As of Feb. 20, their position stood at 117.4 million shares—good for 5.13% of voting power. Company Announcements

Macquarie dropped below the 5% threshold in contractor Downer EDI as of Feb. 20, a separate filing showed, meaning it’s no longer a substantial holder.

A fresh filing from Thursday took it back over the threshold: 33.9 million Downer shares now, which translates to 5.12% voting power. The stake became substantial as of Feb. 23.

These filings tend to be messy. Most of the time, they show stakes tied up in funds run by Macquarie or in stock-lending and borrowing connected to clients, rather than any big bet in one direction.

Macquarie isn’t shifting its fundamental stance. In a Feb. 10 operational briefing, chief executive Shemara Wikramanayake described the December quarter’s trading environment as “satisfactory.” Asset management, she noted, saw a lift from divestment gains. Macquarie

Still, the downside isn’t hard to spot: Macquarie’s momentum can slip fast if global risk appetite dries up or market volatility and trading volume drop off. Those disclosed stakes? They can just as swiftly unwind, whether through security recalls or shifting client positions.

Eyes turn to MQG in the next session to see if Thursday’s rally sticks as the broader market moves. Looking ahead, Macquarie’s full-year results are penciled in for Friday, May 8. Shares go ex-dividend Monday, May 18, and the payout comes July 2.

Stock Market Today

  • Marvell Joins S&P 500, Faces Market Volatility Amid AI Chip Demand
    June 10, 2026, 5:07 AM EDT. Marvell Technology shares fell 7.6% to $266.88 after a 9% rally upon news of inclusion in the S&P 500 effective June 22. The semiconductor maker's market cap stands near $238 billion. AI demand and cloud-focused custom chips remain growth drivers, with fiscal Q1 2027 revenue up 28% year-on-year and $10 billion revenue projected for fiscal 2029. However, chip sector volatility and lofty valuation around 92 times earnings raise concerns. The Philadelphia Semiconductor Index dropped 1.9% amid broader tech sell-off. Marvell recently launched its AI-optimized Teralynx T100 switch chip. While index fund buying is expected near the inclusion date, profit-taking on crowded AI bets may temper gains, analysts say.

Latest articles

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

10 June 2026
Roche’s participation certificates climbed 1.07% to CHF 322.20 after announcing a $2.3 billion deal with Nurix Therapeutics for late-stage blood-cancer drug bexobrutideg, planned to enter Phase 3 trials this summer in CLL, as investors weigh the asset’s potential to offset losses from expiring patents and drive mid-single-digit sales growth in 2026.
YY Group Shares Jump Premarket on Humanoid Robot Move

YY Group Shares Jump Premarket on Humanoid Robot Move

10 June 2026
YYGH jumped to $0.19 in early pre-market after announcing deployment of Unitree G1 humanoid robots for facility management, aiming to turn operational know-how into higher-margin data assets, but the stock remains volatile near record lows after a recent reverse split and has not confirmed robot-driven revenue or margin gains.
Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

10 June 2026
Tencent shares jumped 3.22% to HK$467.80 after the company priced a larger-than-expected US$4.66 billion dual-currency bond deal, drawing over US$17 billion in orders and allowing tighter pricing, as investors weighed Tencent’s ability to fund rising AI investments while maintaining strong cash flow and ongoing share buybacks.
PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

10 June 2026
Paranovus Entertainment Technology shares jumped 19.6% premarket after filing plans for an at-the-market share sale of up to $194.99 million—an unusually large amount compared to its $1.07 million market value—raising dilution risks as the company can sell shares at prevailing prices with no minimums, while recent trading has been highly volatile and underlying operations remain limited.
Marvell Is Now in the S&P 500. The Focus Turns to Its Next Move

Marvell Is Now in the S&P 500. The Focus Turns to Its Next Move

10 June 2026
Marvell plunged 7.6% to $266.88 after Monday’s S&P 500-driven surge, as semiconductor stocks sold off despite the chipmaker’s looming June 22 index inclusion and strong AI demand; shares had soared 59% since May 27 on bullish custom-chip forecasts, but high valuation and sector volatility now threaten further gains.
Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus
Previous Story

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Healthcare Triangle (HCTI) stock jumps 66% premarket on Malaysia TNG eWallet mental-health deal
Next Story

Healthcare Triangle (HCTI) stock jumps 66% premarket on Malaysia TNG eWallet mental-health deal

Go toTop